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Omalizumab, an Anti-IgE mAb,
Receives Approval for the Treatment
of Chronic Idiopathic/Spontaneous
Urticaria
Keith C.P. Wu1 and Zarif K. Jabbar-Lopez1
Omalizumab, an anti-IgE mAb, has recently been approved by the US
Food and Drug Administration (FDA) and European Medicines Agency
(EMA) for the treatment of chronic idiopathic urticaria. Saini et al. (2014)
(this issue) report on ASTERIA I, a 40-week randomized, double-blinded,
placebo-controlled phase III trial evaluating omalizumab for the treatment
of this disease.
Journal of Investigative Dermatology (2015) 135, 13–15; doi:10.1038/jid.2014.362
The burden of disease
In this issue, Saini et al. (2014) report on
ASTERIA I, a phase III clinical trial of
omalizumab for the treatment of
chronic idiopathic urticaria (CIU) (also
referred to as chronic spontaneous
urticaria). CIU is a common derma-
tosis, with a prevalence of 0.5–1% and
a peak incidence between 20 and 40
years of age, although patients of any
age can be affected. Women are twice
as likely as men to suffer from CIU
(Maurer et al., 2011). CIU is defined
by itchy red patches and wheals (hives)
affecting the skin; these can range from
a few millimeters to several centimeters
in diameter. Although individual wheals
may come and go, typically lasting
2–24 hours, to meet the criteria of CIU,
the condition must persist for over 6
weeks without any identifiable under-
lying triggers (e.g., drugs, physical stimu-
lus, infection, or allergen). In addition to
red patches and wheals, up to two-thirds
of patients with CIU will have deeper
swelling of the skin (known as angioe-
dema), which typically affects the eye-
lids, lips, and genitals (Maurer et al.,
2011). Angioedema is more often pain-
ful than pruritic and may last 2–3 days.
Patients may also have associated fati-
gue and arthralgias.
As well as being relatively common,
CIU can have detrimental effects
on a patient’s quality of life, with
some patients rating the impact of CIU
as highly as ratings for ischemic
heart disease (O’Donnell et al., 1997).
Furthermore, CIU may persist for 3–5
years in 50% of patients and for over
10 years in 20%. CIU is more likely to
have a prolonged course in patients with
(i) greater severity of disease, (ii) angioe-
dema, (iii) a positive autologous
serum skin test, and (iv) a physical
trigger to their urticaria (Maurer et al.,
2011). CIU can also have significant
economic costs; one study of patients
treated with H1-antihistamines (patients
on corticosteroids and immuno-
suppressants were excluded) showed
that the annual cost was 4$2,000
per patient (the majority being direct
costs, e.g., medication and hospital
visits; indirect costs included loss of
salary due to outpatient attendance
or absence from work; Delong et al.,
2008).
CIU may have an underlying autoim-
mune basis in approximately 30–50% of
patients; these patients demonstrate
functional IgG autoantibodies against
the high-affinity IgE receptor (FceRI) or
IgE. These antibodies induce the release
of histamine and other mediators
(including proteases, eicosanoids, and
cytokines) from mast cells (the principal
effector cell in urticaria) and basophils
(Hide et al., 1993). A group of patients,
who produce IgE against autoantigens,
including thyroid peroxidase, has also
been identified (Altrichter et al., 2011).
CIU patients with autoantibodies
reportedly have more severe urticaria
compared with CIU patients without
autoantibodies, and they may be more
resistant to treatment (Sabroe et al.,
1999). Interestingly, CIU patients
with detectable autoantibodies against
the high-affinity IgE receptor or IgE have
a strong association with HLA DRB1*04
(DR4) and its associated allele,
DQB1*0302 (DQ8; O’Donnell et al.,
1999). Further evidence that CIU
may have an underlying autoimmune
mechanism, at least in some patients,
comes from the observation that CIU is
associated with several autoimmune
conditions, including type I diabetes,
rheumatoid arthritis, autoimmune
thyroid disease, and systemic lupus
erythematosus (Confino-Cohen et al.,
2012).
Current licensed treatment options
for CIU are limited
Despite CIU being a relatively
common and potentially debilitating
disease, there are few licensed treat-
ment options. International guidelines
(Figure 1; Zuberbier et al., 2014)
recommend second-generation (non-
sedating) H1-antihistamines, on a
regular basis, as first-line treatment for
CIU. Although this is the mainstay of
treatment for most patients, many do not
experience adequate relief of symptoms.
A sedating ‘‘classical’’ H1-antihistamine,
such as hydroxyzine, at nighttime,
may be beneficial. Cooling topical
treatments, such as menthol in
aqueous cream, may provide
symptomatic, soothing relief for some
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patients. If symptoms persist after 2
weeks, guidelines recommend an
increase of up to four times the
normally prescribed dose of H1-
antihistamines. Studies investigating the
effectiveness of higher doses of H1-
antihistamines for CIU are mixed, with
responses ranging from 5 to 75% (Asero,
2007; Staevska et al., 2010). The
differences in response may, in part, be
due to the different H1-antihistamines
prescribed. Furthermore, some studies
may have been based in tertiary referral
centers where there may be higher
proportions of difficult-to-treat patients.
In any case, the use of H1-antihi-
stamines above standard dosages is
‘‘off-license’’.
If symptoms persist, despite higher
doses of H1-antihistamines, guidelines
recommend the addition of ciclosporin,
montelukast (leukotriene antagonist), or
omalizumab.(Zuberbier et al., 2014).
When these guidelines were written,
all three third-line drugs (including
omalizumab) were used ‘‘off-label’’ in
the treatment of CIU. In addition to
these treatments, other options reported
in the literature include azathioprine,
dapsone, hydroxychloroquine, Igs,
methotreaxate, and sulfasalazine.
Again, all these drugs are used off-
label, with limited definitive evidence
for their efficacy in CIU. Guidelines also
suggest a short trial of systemic
corticosteroids for exacerbations. One
study showed that systemic cortico-
steroids could induce remission in
B50% of patients, although patients
included in the study had not regularly
used H1-antihistamines above the
licensed doses, and it was uncertain
how long these patients had CIU prior
to receiving systemic corticosteroid
treatment. However, long-term use
of systemic corticosteroids should be
avoided, because of potential side
effects associated with prolonged use,
including hypertension, glucose
intolerance, and osteoporosis.
Omalizumab as a treatment option
for CIU
In light of CIU being a relatively com-
mon disease that can impact negatively
on quality of life, and with limited
licensed treatment options, there is
clearly an unmet demand for treatment.
The article by Saini et al. (2014) in this
issue, reporting the results of ASTERIA I,
a randomized, double-blinded, placebo-
controlled phase III trial of omalizumab
for the treatment of CIU, is therefore of
great interest. Omalizumab, a recombi-
nant humanized mAb, is already
licensed for the treatment of mode-
rate–severe allergic asthma, with an
established safety record for its use in
this condition. Omalizumab binds to
free IgE in serum and inhibits IgE bind-
ing to FceRI on effector cells, including
mast cells and basophils (it cannot bind
to FceRI-bound IgE; Chang et al.,
2014). Although omalizumab has no
direct effect on FceRI expression,
sequestration of free IgE results in
downregulation of FceRI on effector
cells. It is beyond the scope of this
study to discuss the downstream effects
of these actions, but a comprehensive
commentary on this subject has recently
been published (Chang et al., 2014).
Two phase III clinical trials on oma-
lizumab for the treatment of CIU have
been published by the same, well-
regarded, Consortium. Supplementary
Table S1 online of the article (Saini
et al., 2014) summarizes the key
design features of these studies,
but briefly (i) the GLACIAL study
(Kaplan et al., 2013) evaluated the
safety of omalizumab in patients
already receiving typical second-line
therapy (e.g., four times approved
doses of H1-antihistamines, H2-anti-
histamines, or leukotriene antagonists),
and the primary outcome was the
percentage of participants with adverse
events (AEs); (ii) the ASTERIA II study
(Maurer et al., 2013) evaluated the
Clinical Implications
 H1-antihistamines were previously the only therapy with regulatory
approval for the treatment of chronic idiopathic urticaria (CIU), although
many patients do not respond adequately to this treatment.
 Phase III clinical trials support the efficacy and safety of omalizumab
for the treatment of CIU; it has now been approved by the US Food
and Drug Administration and European Medicines Agency for this
indication.
 Omalizumab, a recombinant humanized anti-IgE mAb, is recommended as
third-line treatment (as are ciclosporin and leukotriene antagonists) for
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Figure 1. Treatment ladder for chronic idiopathic urticaria. H1-antihistamines, on a regular basis, should
be used as first-line treatment. If symptoms persist after 2 weeks, increase dose up to four times the
normally prescribed dose, as second-line treatment. If symptoms continue after a further 1–4 weeks, add
either ciclosporin, montelukast (leukotriene antagonist), or omalizumab (add-on therapies are listed in
alphabetical order and do not represent ranking). Short courses of corticosteroids (up to 10 days) may be
prescribed during exacerbations of chronic idiopathic urticaria if required. Adapted from the figure in the
reference of Zuberbier et al. (2014).
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efficacy of three different doses of
omalizumab, in patients who remained
symptomatic despite approved doses
of H1-antihistamines, over a 12-week
treatment and 16-week observation
period, and the primary outcome was
the change in the weekly itch severity
score (ISS) from baseline to week
12 of treatment. A critical appraisal of
ASTERIA II has been recently published
(Durack and Matin, 2014).
ASTERIA I is a similar, although sepa-
rate, study from ASTERIA II, but with a
treatment period that is twice as long
(24 weeks vs. 12 weeks); the follow-up
periods were the same in both studies
(16 weeks). As with ASTERIA II, the
primary outcome was the change in
weekly ISS from baseline to week 12.
All three omalizumab treatment groups
achieved a lower weekly ISS at week 12
compared with placebo (Supplementary
Table S2 online), this appeared to be
dose dependent. These results were
consistent with the primary end point
of ASTERIA II (Maurer et al., 2013).
Interestingly, although improvements in
ISS are maintained after 12 weeks, there
does not appear to be any further
improvement in this end point after
this period (Supplementary Tables S2
and S4 online). No group returned to
their baseline mean weekly ISS after the
16-week observation period, including
the placebo group (Supplementary
Figure S2 online). As the authors point
out, this could suggest that a proportion
of patients experienced ‘‘spontaneous’’
remission (or at least remission while on
standard doses of H1-antihistamines).
Safety
AEs, which were suspected to be caused
by omalizumab, appeared to be dose
dependent (Supplementary Table S3
online), although the authors state ‘‘the
dose-dependent trend was not clustered
by a specific AE type’’. No statistical
analysis was reported on these figures,
as safety was not a primary outcome in
ASTERIA I. However, the previously
published phase III GLACIAL study pri-
marily evaluated the safety of omalizu-
mab in patients already receiving
standard combination CIU treatment
and found the incidence of AEs to be
similar between placebo and treatment
groups (e.g., the proportion of patients
with Z1 AE suspected to be caused by
study drug was 13.3% in the placebo
group compared with 11.1% in the
omalizumab 300 mg group; Kaplan
et al., 2013).
The future
Undoubtedly, the well-conducted phase
III clinical trials and recent FDA/EMA
approval of omaluzimab for CIU are
exciting. It will be interesting to see
how writers of guidelines and health
economists view the recent approval
and whether this will affect the avail-
ability and ranking of omalizumab in
the management of CIU. However, as
with other biologics, omalizumab
has significant cost implications, and
its effectiveness compared with other
third-line agents (ciclosporin or monte-
lukast) has yet to be established. Further-
more, not all patients responded to
omalizumab treatment; future studies
could be directed at investigating bio-
markers to predict responses to therapy.
Finally, it may be interesting to investi-
gate the effects of omalizumab in
other diseases characterized by elevated
IgE levels, which in dermatology could
include atopic dermatitis and bullous
pemphigoid.
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